Gilead Sciences Reports Softer Sovaldi Revenues
October 28, 2014 at 17:15 PM EDT
Gilead Sciences, Inc. (NASDAQ: GILD) reported significantly softer sales of its blockbuster Hep C drug, Sovaldi. Gilead ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.